

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. (**Currently Amended**) ~~Pharmaceutical~~ A pharmaceutical composition comprising 5 to 20% of an idazoxan salt or of idazoxan hydrate, 10 to 40% of microcrystalline cellulose, 1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and from 29.5% to 84.8% of lactose, with respect to the total mass.

2. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1, ~~in which~~ wherein the salt is the hydrochloride.

3. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form I characterized by the X-ray diffraction spectrum presented in Figure 1.

4. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form I characterized by an X-ray diffraction spectrum comprising characteristic peaks at approximately 4.0200, 6.6400,

6.9000, 7.0800, 8.0800, 9.0000, 9.9600, 9.9600, 10.8400, 11.7200, 12.1400, 12.3800, 12.9800, 13.3000, 13.5200, 14.9000, 15.0600, 15.2400 and 21.4000 degrees θ .

5. **(Currently Amended)** ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form I characterized by an X-ray diffraction spectrum comprising characteristic peaks at approximately 4.0200, 6.6400, 6.9000, 7.0800, 8.0800, 9.0000, 9.9600, 9.9600, 10.8400, 11.7200, 12.1400, 12.3800, 12.9800, 13.3000, 13.5200, 14.9000, 15.0600, 15.2400 and 21.4000 degrees θ and lacking at least one peak at approximately 4.7400, 5.7200, 8.9200, 16.8600 or 18.9000 degrees θ .

6. **(Currently Amended)** ~~Pharmaceutical~~ The pharmaceutical composition according to Claims 3 to 5, ~~in which the~~ 1 or 2, wherein said polymorph of form I is characterized by a differential thermal analysis thermogram exhibiting a single maximum value at approximately 207.5 ± 0.2 .

7. **(Currently Amended)** ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form III characterized by the X-ray diffraction spectrum presented in Figure 3.

8. **(Currently Amended)** ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form III characterized by

an X-ray diffraction spectrum comprising characteristic peaks at approximately 4.0400, 4.7000, 5.7400, 6.6200, 6.9200, 7.4600, 8.0400, 8.7800, 8.9800, 9.9800, 10.8200, 11.4600, 11.6400, 12.3200, 12.9400, 13.5400, 14.2400, 15.0600, 15.6200 and 16.8400 degrees θ .

9. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~Claims 7 and 8, in which the~~ claim 7, wherein said polymorph of form III is characterized by a differential thermal analysis thermogram exhibiting a single maximum value at approximately 203.8 ± 0.5 .

10. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form IV characterized by the X-ray diffraction spectrum presented in Figure 4.

11. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form IV characterized by an X-ray diffraction spectrum comprising characteristic peaks at approximately 4.8000, 5.9000, 6.8400, 7.3200, 8.0800, 8.6600, 9.4600, 9.6800, 11.1600, 11.4000, 11.9000, 12.2200, 12.6800, 13.8400, 14.4200, 14.9800 and 18.1000 degrees θ .

12. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1 or 2, ~~in which the~~ wherein said idazoxan is the polymorph of form IV characterized by

an X-ray diffraction spectrum comprising characteristic peaks at approximately 4.8000, 5.9000, 6.8400, 7.3200, 8.0800, 8.6600, 9.4600, 9.6800, 11.1600, 11.4000, 11.9000, 12.2200, 12.6800, 13.8400, 14.4200, 14.9800 and 18.1000 degrees θ and lacking at least one peak at approximately 6.6800, 13.5400, 15.6800, 16.8600 or 18.9000 degrees θ .

13. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~Claims 10 to 12, in which the~~ Claim 10, wherein said polymorph of form IV is characterized by a differential thermal analysis thermogram exhibiting a single maximum value at approximately 205.3 ± 0.5 .

14. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1, ~~in which the~~ wherein said idazoxan monohydrate is the polymorph of form V characterized by the X-ray diffraction spectrum presented in Figure 5.

15. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1, ~~in which the~~ wherein said idazoxan monohydrate is the polymorph of form V characterized by an X-ray diffraction spectrum comprising characteristic peaks at approximately 5.0400, 5.8400, 7.9400, 9.2800, 9.4400, 10.1200, 12.0200, 12.5600, 12.9200, 13.7400, 13.9400, 14.5200, 14.8200, 15.2800, 16.2800 and 16.7400 degrees θ .

16. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 1, ~~in which the~~ wherein said idazoxan monohydrate is the polymorph of form V characterized by an X-ray diffraction spectrum comprising characteristic peaks at approximately 5.0400, 5.8400, 7.9400, 9.2800, 9.4400, 10.1200, 12.0200, 12.5600, 12.9200, 13.7400, 13.9400, 14.5200, 14.8200, 15.2800, 16.2800 and 16.7400 degrees θ and lacking at least one peak at approximately 4.7400, 6.6800, 7.5000, 8.9200, 11.5200, 14.3000, 15.6800 or 18.9000 degrees θ .

17. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to Claims 14 to 16, ~~in which the~~ wherein said idazoxan monohydrate polymorph of form V is characterized by a differential thermal analysis thermogram exhibiting a single maximum value at approximately 205.6 ± 0.4 .

18. (**Currently Amended**) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~Claims 1 to 17, in which~~ claim 1 or 2, wherein the lubricant is glyceryl behenate.

19. (**Currently Amended**) ~~Composition~~ The pharmaceutical composition according to ~~Claims 1 to 18, which is provided~~ claim 1 or 2, said composition is in a form suitable for oral administration.

20. (**Currently Amended**) ~~Tablets,~~ A tablet comprising a pharmaceutical composition according to ~~Claims 1 to 19,~~ Claim 1 or 2.

21. (**Currently Amended**) Tablets, A tablet according to Claim 20, ~~characterized in that they have~~ wherein said tablet has a mass of between 50 and 1 000 mg, ~~preferably between 100 and 600 mg.~~

22. (**Currently Amended**) Tablets, A tablet according to ~~Claims 20 and 21,~~ Claim 21, ~~characterized in that they are~~ wherein said tablet is provided in a leaktight packaging.

23. (**Currently Amended**) Tablets, A tablet according to Claim 22, ~~characterized in that~~ wherein the packaging leaktight to water vapour is composed of a tablet bottle made of polypropylene or of high-density polyethylene, of an aluminium sachet ~~or, and preferably, or~~ of an all-aluminium blister pack.

24. (**Currently Amended**) ~~Process~~ A process for the manufacture of a tablet according to ~~one of Claims 20 to 23,~~ Claim 20, said process comprising a stage of direct tableting of a powder mixture.

25. (**Currently Amended**) ~~Process~~ The process for the manufacture of a tablet according to Claim 24, ~~characterized in that the~~ wherein said tableting is preceded by a stage of dry granulation, ~~for example by compacting.~~

26. (**Currently Amended**) ~~Manufacturing~~ The manufacturing process according to Claim 25, ~~in which~~ wherein the active principle has a particle size, expressed by its mean diameter, of between 50 and 250 microns.

27. (**Currently Amended**) ~~Manufacturing~~ The manufacturing process according to Claim 25, ~~in which~~ wherein the active principle has a mean particle size ~~preferably of between~~ 75 and 150 microns ~~and more particularly in the region of 100 to 125 microns.~~

28. (**Currently Amended**) ~~Manufacturing~~ The manufacturing process according to ~~Claims 24 to 27, in which~~ Claim 24, wherein the active principle has a bulk density of between 0.4 and 0.8. ~~0.8 and preferably between 0.5 and 0.7 and more preferably still in the region of 0.6.~~

29. (**Currently Amended**) ~~Use of a composition according to Claims 1 to 19 or of a tablet according to Claims 20 to 23 as medicament intended for the preventive and/or curative treatment of~~ A method for treating a pathology selected from the group consisting of depression, Parkinson's disease and severe psychotic disorders, such as schizophrenia and schizoaffective disorders, said method comprising administering the pharmaceutical composition of Claim 1 to a patient in need thereof.

30. (**Currently Amended**) ~~Use of a composition according to Claims 1 to 19 or of a tablet according to Claims 20 to 23,~~ A method of treating a severe psychotic disorder, said

method comprising administering the pharmaceutical composition of Claim 1 to a patient in need thereof in combination with an atypical antipsychotic neuroleptic exhibiting a greater antagonist affinity for the dopamine D₂ receptor than is its antagonist affinity for the α_2 -adrenoreceptor, as ~~medicament for the preventive and/or curative treatment of severe psychotic disorders, such as schizophrenia and schizoaffective disorders.~~ α_2 -adrenoreceptor.

31. (Currently Amended) Use according to ~~Claim 30, characterized in that~~ The method according to Claim 30, wherein the said atypical neuroleptic is chosen from olanzapine, quetiapine, risperidone, sertindole or ziprasidone.

32. (Currently Amended) Polymerie A polymeric form I of idazoxan wherein the X-Ray spectra comprises specific peaks at about 4,0200, 6,6400, 6,9000, 7,0800, 8,0800, 9,0000, 9,9600, 9,9600, 10,8400, 11,7200, 12,1400, 12,3800, 12,9800, 13,3000, 13,5200, 14,9000, 15,0600, 15,2400 and 21,4000 degrees θ .

33. (Currently Amended) Polymerie A polymeric form I of idazoxan wherein the X-Ray spectra comprises specific peaks at about 4,0200, 6,6400, 6,9000, 7,0800, 8,0800, 9,0000, 9,9600, 9,9600, 10,8400, 11,7200, 12,1400, 12,3800, 12,9800, 13,3000, 13,5200, 14,9000, 15,0600, 15,2400 and 21,4000 degrees θ and lacking at least one peak at about 4,0200, 6,6400, 6,9000, 7,0800, 8,0800, 9,0000, 9,9600, 9,9600, 10,8400, 11,7200, 12,1400, 12,3800, 12,9800, 13,3000, 13,5200, 14,9000, 15,0600, 15,2400 and 21,4000 degrees θ .

34. (**Currently Amended**) ~~Polymeric~~ A polymeric form I of idazoxan wherein the differential thermal analysis thermogram exhibiting a single maximum value at approximately 207.5 ± 0.2 .

35. (**Currently Amended**) ~~Polymeric~~ A polymeric form II of idazoxan wherein the X-Ray spectra comprises the specific peaks at about 4.7400, 5.7200, 6.6800, 7.5000, 8.9200, 9.9600, 11.5200, 12.3000, 12.9400, 13.5400, 14.3000, 15.6800, 16.8600 and 18.9000 degrees θ .

36. (**Currently Amended**) ~~Polymeric~~ A polymeric form II of idaxozan wherein the differential thermal analysis thermogram exhibiting a single maximum value at approximately 203.0 ± 0.4 .

37. (**Currently Amended**) ~~Polymeric~~ A polymeric form III of idazoxan wherein the X-Ray spectra comprises the specific peaks at about 4,0400, 4.7000, 5.7400, 6.6200, 6.9200, 7.4600, 8.0400, 8.7800, 8.9800, 9.9800, 10.8200, 11.4600, 11.6400, 12.3200, 12.9400, 13.5400, 14.2400, 15.0600, 15.6200 and 16.8400 degrees θ .

38. (**Currently Amended**) ~~Polymeric~~ A polymeric form III of idazoxan wherein the differential thermal analysis thermogram exhibiting a single maximum value at approximately 203.8 ± 0.5 .

39. (**Currently Amended**) ~~Polymerie~~ A polymeric form IV of idazoxan wherein the X-Ray spectra comprises the specific peaks at about 4.8000, 5.9000, 6.8400, 7.3200, 8.0800, 8.6600, 9.4600, 9.6800, 11.1600, 11.4000, 11.9000, 12.2200, 12.6800, 13.8400, 14.4200, 14.9800 and 18.1000 degrees θ .

40. (**Currently Amended**) ~~Polymerie~~ A polymeric form IV of idazoxan wherein the X-Ray spectra comprises the specific peaks at about 4.8000, 5.9000, 6.8400, 7.3200, 8.0800, 8.6600, 9.4600, 9.6800, 11.1600, 11.4000, 11.9000, 12.2200, 12.6800, 13.8400, 14.4200, 14.9800 and 18.1000 degrees θ and lacking at least one peak at about 6.6800, 13.5400, 15.6800, 16.8600 or 18.9000 degrees θ .

41. (**Currently Amended**) ~~Polymerie~~ A polymeric form IV of idazoxan wherein the differential thermal analysis thermogram exhibiting a single maximum value at approximately 205.3 ± 0.5 .

42. (**Currently Amended**) ~~Polymerie~~ A polymeric form V of idazoxan wherein the X-Ray spectra comprises the specific peaks at about 5.0400, 5.8400, 7.9400, 9.2800, 9.4400, 10.1200, 12.0200, 12.5600, 12.9200, 13.7400, 13.9400, 14.5200, 14.8200, 15.2800, 16.2800 and 16.7400 degrees θ .

43. (**Currently Amended**) ~~Polymeric~~ A polymeric form V of idazoxan wherein the X-Ray spectra comprises the specific peaks at about 5.0400, 5.8400, 7.9400, 9.2800, 9.4400, 10.1200, 12.0200, 12.5600, 12.9200, 13.7400, 13.9400, 14.5200, 14.8200, 15.2800, 16.2800 and 16.7400 degrees θ and lacking at least one peak at about 4.7400, 6.6800, 7.5000, 8.9200, 11.5200, 14.3000, 15.6800 or 18.9000 degrees θ .